
GlaxoSmithKline, UK house prices, and Sovereign Metals with Alan Green
UK Investor Magazine
00:00
Ador, the Company's Flagship Project, Has Grown Revenues by Ten %
Ador is developing molecular bi biology solutions to provide rapid testing for bacterial, viral or fungal infections using a dna and arinasa sampling. Networking siber division revenues fell following the sale of n g soft, but it's realized a capital gain of 13 million dollars from that. The company expects to deliver revenues and abida substantially ahead of market expectations, with growth of over forty % year on year. And i think you'll see in the coming weeks, the term the company is going to er. It will be a porting to the market.
Transcript
Play full episode